Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554807 | 1.00 | CA1 (0.55) | CA1CA2CA12CA9LCK | |
| SCHEMBL1096991 | 0.88 | GAA (0.53) | CA1CA2CA12CA9LCK | |
| SCHEMBL5099200 | 0.88 | GAA (0.53) | CA1CA2CA12CA9LCK | |
| SCHEMBL2774619 | 0.88 | LCK (0.54) | CA1CA2CA12CA9LCK | |
| SCHEMBL1097015 | 0.88 | HSD17B10 (0.49) | CA1CA2CA12CA9LCK | |
| SCHEMBL1096723 | 0.88 | CA1 (0.46) | CA1CA2CA12CA9LCK | |
| SCHEMBL14123786 | 0.87 | HSD17B10 (0.56) | CA1CA2CA12CA9LCK | |
| Hydrochloric Acid SCHEMBL1096252 | 0.87 | CA1 (0.45) | CA1CA2CA12CA9LCK | |
| Hydrochloric Acid SCHEMBL1098120 | 0.86 | HSD17B10 (0.47) | CA1CA2CA12CA9LCK | |
| SCHEMBL1098529 | 0.86 | HSD17B10 (0.47) | CA1CA2CA12CA9LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116675642-A | Preparation method of chiral aporphine alkaloid | 智简生物科技(上海)有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| EP-2148865-B1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-1893575-B1 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H LUNDBECK AS (DK) | 2017-01-11 | — | — | EP | disclosed |
| US-8153808-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153808-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153808-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| CN-102264700-A | Dihydropyridone amides used as medicaments for treatment of autoimmunity and inflammatory disorders | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2382192-A2 | DIHYDROPYRIDONE AMIDES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072647-A2 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GRENENTECH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2148865-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | Genentech, Inc. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-7629473-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2009-12-08 | — | — | US | disclosed |
| WO-2008137408-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | GENENTECH, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1893575-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H.Lundbeck A/S (DK) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134499-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5017569-A | Cephalosporin derivatives | ICI PHARMA (FR) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137394-A1 | PYRAZOLE INHIBITORS OF WNT SIGNALING | WNT1, WNT3A, CTNNB1 | CA1 4784/4885CA2 4729/4885CA12 4866/4885 |
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | CYP11B2, CYP1A2, CYP4B1 | CA1 3108/4885CA2 3205/4885CA12 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.